Common cold combats COVID-19

15-Jun-2021 1:05 PM EDT, by Yale University

Newswise — Exposure to the rhinovirus, the most frequent cause of the common cold, can protect against infection by the virus which causes COVID-19, Yale researchers have found.

In a new study, the researchers found that the common respiratory virus jump-starts the activity of interferon-stimulated genes, early-response molecules in the immune system which can halt replication of the SARS-CoV-2 virus within airway tissues infected with the cold.

Triggering these defenses early in the course of COVID-19 infection holds promise to prevent or treat the infection, said Ellen Foxman, assistant professor of laboratory medicine and immunobiology at the Yale School of Medicine and senior author of the study. One way to do this is by treating patients with interferons, an immune system protein which is also available as a drug.

"But it all depends upon the timing," Foxman said.

The results were published June 15th in the Journal of Experimental Medicine.

Previous work showed that at the later stages of COVID-19, high interferon levels correlate with worse disease and may fuel overactive immune responses. But recent genetic studies show that interferon-stimulated genes can also be protective in cases of COVID-19 infection.

Foxman's lab wanted to study this defense system early in the course of COVID-19 infection.

Since earlier studies by Foxman's lab showed that common cold viruses may protect against influenza, they decided to study whether rhinoviruses would have the same beneficial impact against the COVID-19 virus. For the study, her team infected lab-grown human airway tissue with SARS-CoV-2 and found that for the first three days, viral load in the tissue doubled about every six hours. However, replication of the COVID-19 virus was completely stopped in tissue which had been exposed to rhinovirus. If antiviral defenses were blocked, the SARS-CoV-2 could replicate in airway tissue previously exposed to rhinovirus.

The same defenses slowed down SARS-CoV-2 infection even without rhinovirus, but only if the infectious dose was low, suggesting that the viral load at the time of exposure makes a difference in whether the body can effectively fight the infection.

The researchers also studied nasal swab samples from patients diagnosed close to the start of infection. They found evidence of rapid growth of SARS-CoV-2 in the first few days of infection, followed by activation of the body's defenses. According to their findings, the virus typically increased rapidly for the first few days of infection, before host defenses kicked in, doubling about every six hours as seen in the lab; in some patients the virus grew even faster.

"There appears to be a viral sweet spot at the beginning of COVID-19, during which the virus replicates exponentially before it triggers a strong defense response," Foxman said.

Interferon treatment holds promise but it could be tricky, she said, because it would be mostly effective in the days immediately after infection, when many people exhibit no symptoms. In theory, interferon treatment could be used prophylactically in people at high risk who have been in close contact with others diagnosed with COVID-19. Trials of interferon in COVID-19 are underway, and so far show a possible benefit early in infection, but not when given later.

These findings may help explain why at times of year when colds are common, rates of infections with other viruses such as influenza tend to be lower, Foxman said. There are concerns that as social distancing measures ease, common cold and flu viruses -- which have been dormant over the past year -- will come back in greater force. Interference among respiratory viruses could be a mitigating factor, creating an "upper limit" on the degree to which respiratory viruses co-circulate, she said.

"There are hidden interactions between viruses that we don't quite understand, and these findings are a piece of the puzzle we are just now looking at," Foxman said.

###

Nagarjuna R. Cheemarla, a postdoctoral associate in Foxman's lab, was first author of the study, which was carried out by a team of Yale scientists in the Departments of Laboratory Medicine, Immunobiology, and Genetics.

Other Yale authors included Timothy Watkins, Valia Mihaylova, Bao Wang, Marie Landry, Dejian Zhao, and Guilin Wang.



Filters close

Showing results

110 of 6111
Released: 2-Aug-2021 6:05 PM EDT
Rethinking Remdesivir
University of California San Diego Health

UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.

Newswise: Researchers from Hackensack Meridian University Medical Center and Colleagues Develop New Model to Help Clinicians Predict Risk of Death in Patients Hospitalized with COVID-19
Released: 2-Aug-2021 4:25 PM EDT
Researchers from Hackensack Meridian University Medical Center and Colleagues Develop New Model to Help Clinicians Predict Risk of Death in Patients Hospitalized with COVID-19
Hackensack Meridian Health

New COVID-19 40-day mortality risk model, published in The Public Library of Science ONE, has potential for use in patient treatment planning, comparisons of therapeutic strategies, and public-health preparations.

Released: 2-Aug-2021 4:05 PM EDT
Town Hall on Effectiveness of COVID-19 Vaccination in Immunosuppressed Patients Hosted by the American College of Rheumatology
American College of Rheumatology (ACR)

How effective COVID-19 vaccines have been in immunosuppressed and rheumatic disease patients remains an incompletely answered question. The American College of Rheumatology (ACR) has organized an expert panel to share what we are learning from real-world data and answer questions.

Released: 2-Aug-2021 2:00 PM EDT
CDC withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test does not mean the test failed
Newswise

Social media is now rife with claims about why the CDC is withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test after December 2021.

Newswise: Existing Drug Is Shown to Inhibit Virus That Causes COVID-19
Released: 2-Aug-2021 1:30 PM EDT
Existing Drug Is Shown to Inhibit Virus That Causes COVID-19
Argonne National Laboratory

Scientists using the Advanced Photon Source have discovered that a drug used to fight tumors in animals might be effective against many types of coronaviruses, including SARS-CoV-2.

Released: 2-Aug-2021 11:25 AM EDT
Award-Winning Journalist and CDC Principal Investigator to Serve as ACR Convergence 2021 Keynote Speaker
American College of Rheumatology (ACR)

Convergence 2021, the annual meeting of the American College of Rheumatology (ACR), returns to a virtual meeting platform Nov. 1 - 10. This year’s meeting will include presentations from over 320 clinicians, researchers and health experts, including this year’s keynote speaker, Dr. Seema Yasmin.

Newswise: COVID-19: Small Sign of Hope as Vaccinations Rise
Released: 2-Aug-2021 10:45 AM EDT
COVID-19: Small Sign of Hope as Vaccinations Rise
Cedars-Sinai

As COVID-19 cases spike in Los Angeles and throughout the Golden State, driven by the spread of the delta variant among unvaccinated residents, there may be a small sign of hope: More people are finally getting their shot.

Newswise: New Evidence Shows the COVID-19 Delta Variant Rapidly Rising
Released: 31-Jul-2021 10:05 AM EDT
New Evidence Shows the COVID-19 Delta Variant Rapidly Rising
University of Miami Health System, Miller School of Medicine

The University’s coronavirus sequencing effort uncovered that there are several variants present in its patient population, but Delta is chief among them and easily transmitted. And its presence is likely triggering a local surge in the infectious disease. University of Miami researchers and physicians are seeing firsthand how rapidly the Delta variant of COVID-19 is spreading through the local population.


Showing results

110 of 6111

close
2.09819